Navigation Links
Bayer and Onyx Announce Nexavar Data Presentations at 35th European Society for Medical Oncology Congress
Date:10/7/2010

MILAN, Oct. 7 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that more than 20 studies evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, October 8-12, 2010 in Milan, Italy.

"It's been almost five years since the approval of Nexavar in its first indication, advanced kidney cancer, and since that time the continuum of development in other areas has produced clinically significant findings, leading to a second approval in unresectable liver cancer," said Dimitris Voliotis, Vice President, Global Clinical Development Oncology, Bayer HealthCare. "Our dedication to the development of Nexavar is demonstrated by the array of data being presented at this year's ESMO Congress as well as the ongoing clinical trial program evaluating Nexavar in a variety of treatment settings and patient types."

Nexavar's Differentiated Mechanism

Nexavar, an oral anti-cancer therapy, is currently approved in more than 95 countries for liver cancer where it remains the only approved systemic agent proven to extend survival and in more than 95 countries for the treatment of patients with advanced kidney cancer.  Nexavar inhibits processes involved in both the tumor cell and tumor vasculature.  In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth.  These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFRB, KIT, FLT-3 and RET.  

Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators.

Important Safety Considerations For Patien
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  There is ... chain organization,s success. The 10th Annual Institute for ... Awards for Excellence in Supply Management is open ... further the understanding and importance of supply management ... leadership and best supply management practices.  Entries are ...
(Date:7/30/2014)... ANN ARBOR, Mich. , July 30, 2014 ... FY2015 first quarter (ending June 27, 2014) financial results on ... results will be released after the close of the market ... to discuss the results at 4:30 p.m. EDT on the ... Richard Kurtz (CEO and Director), Rob Risser ...
(Date:7/30/2014)... BEDFORD, Mass., July 30, 2014  Hologic, Inc. (NASDAQ: ... the third fiscal quarter ended June 28, 2014. ... , Revenues increased 1.0% to $632.6 million, reflecting operational ... 0.5%, compared to the same period in the prior ... four business segments. , Breast Health revenues grew 3.5%. ...
Breaking Medicine Technology:Institute for Supply Management, Michigan State University to recognize companies with excellent supply management practices 2Advanced Photonix to Webcast Fiscal 2015 First Quarter Earnings 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 3Hologic Announces Third Quarter Fiscal 2014 Operating Results 4Hologic Announces Third Quarter Fiscal 2014 Operating Results 5Hologic Announces Third Quarter Fiscal 2014 Operating Results 6Hologic Announces Third Quarter Fiscal 2014 Operating Results 7Hologic Announces Third Quarter Fiscal 2014 Operating Results 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 9Hologic Announces Third Quarter Fiscal 2014 Operating Results 10Hologic Announces Third Quarter Fiscal 2014 Operating Results 11Hologic Announces Third Quarter Fiscal 2014 Operating Results 12Hologic Announces Third Quarter Fiscal 2014 Operating Results 13Hologic Announces Third Quarter Fiscal 2014 Operating Results 14Hologic Announces Third Quarter Fiscal 2014 Operating Results 15Hologic Announces Third Quarter Fiscal 2014 Operating Results 16Hologic Announces Third Quarter Fiscal 2014 Operating Results 17
... N.Y., Jan. 11 Misonix, Inc. (Nasdaq: MSON ... technology, which in Europe is used for the ablation ... has entered into a new, three year, exclusive distribution ... the distribution of the SonaStar(TM) Ultrasonic Surgical Aspirator, the ...
... , WASHINGTON, Jan. 11 The ... star Aaron Boone is featured in January on , Sharing Miracles ... tells the compelling and inspirational stories of real patients. , Sharing Miracles ... sponsored by the Pharmaceutical Research and Manufacturers of America ( ...
Cached Medicine Technology:Misonix Announces New Distribution Agreement for Peru 2Misonix Announces New Distribution Agreement for Peru 3Major League Baseball Star Aaron Boone on 'Sharing Miracles' 2Major League Baseball Star Aaron Boone on 'Sharing Miracles' 3
(Date:7/30/2014)... (PRWEB) July 30, 2014 Good ... featured in an upcoming episode of Innovations with ... Discovery Channel. Dates and show times TBA. , ... Good Neighbor Community Services’ vision to redefine the ... individualized and dynamic services. Through passion, innovation, determination, ...
(Date:7/30/2014)... Volunteers from the Church of Scientology of Denmark ... with massive distribution of Truth About Drugs ... on Strøget, the famous Copenhagen walking street. Popular ... its ambiance, some quarter of a million people stroll ... , These activities are part of a coordinating effort ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 ... of authentication, access management and secure communications solutions ... Imprivata OneSign ® is the most widely selected ... McKesson Paragon or Horizon electronic medical records (EMR) ... increase of about 11 percent in the last ...
(Date:7/30/2014)... (July 30, 2014) The phrase "we caught it early" ... in the midst of a cancer diagnosis. Combating cancer ... to a certain part of the body, gives patients ... breast, skin, colon, prostate and other forms of cancer ... health care providers recommend cancer screenings as a precautionary ...
(Date:7/30/2014)... Atlanta, Georgia (PRWEB) July 30, 2014 ... Business and Technology Alliance of TAG (B&TA), today issued ... 2014 TAG Excalibur Awards. , Interested companies have until ... program after which, Semi-Finalists will be selected by the ... be required to meet with the judges for interviewing ...
Breaking Medicine News(10 mins):Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3
... forget: improving memory in Alzheimer disease mice , ... in memory formation, has been linked to Alzheimer disease. ... have now shown that two different drugs that inhibit ... Alzheimer disease (APP/PS1 mice), leading them to suggest drugs ...
... USA, Inc. announced the signing of a Memorandum of Understanding signifying ... Spray, an all natural, capsaicin-based product for fast relief from allergy ... ... Washington, DC, and Newtown, CT (PRWEB) July 1, 2008 -- ...
... Minn., July 1 Howard Epstein, M.D. has ... medical director for commercial,operations and clinical design. In ... supporting case review and clinician consultation for,integrated health ... Design area, serve as a liaison to Blue ...
... The U.S.,Agency for International Development (USAID) awarded a ... HIV/AIDS in Ethiopia. The program will,provide youth access to ... existing care and prevention programs in five,underserved communities in ... build community networks by means of youth-led volunteer services. ...
... NEW YORK (July 1, 2008) -- Women may ... (CV) drug-treatments for enlarged heart, according to NewYork-Presbyterian ... first time, researchers have uncovered that women derive ... high-blood-pressure-lowering drugs -- losartan and atenolol -- for ...
... toll in outbreak reaches 869, probe expands to include ... 1 (HealthDay News) -- With the number of people ... 869, with 107 hospitalizations, U.S. officials acknowledged Tuesday that ... the contaminant. , The U.S. Food and Drug Administration ...
Cached Medicine News:Health News:JCI online early table of contents: July 1, 2008 2Health News:JCI online early table of contents: July 1, 2008 3Health News:JCI online early table of contents: July 1, 2008 4Health News:JCI online early table of contents: July 1, 2008 5Health News:JCI online early table of contents: July 1, 2008 6Health News:SINOL USA, Inc. and Strategic Pharmaceutical Advisors, Inc. to Enter a Marketing Agreement for SINOL Nasal Spray 2Health News:USAID Announces Youth-Focused HIV/AIDS Programs in Ethiopia 2Health News:Gender differences and heart disease 2Health News:U.S. Officials Stymied in Salmonella Search 2Health News:U.S. Officials Stymied in Salmonella Search 3Health News:U.S. Officials Stymied in Salmonella Search 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: